August 26, 2024 11:36 AM EDT

Another major PBM will cut AbbVie's Humira from its largest commercial formularies

Shelby Livingston

Senior health tech reporter

Cigna’s pharmacy benefit manager Express Scripts said it will remove Humira from its largest commercial drug formularies in 2025 to make way for its biosimilars …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Another major PBM will cut AbbVie's Humira from its largest commercial formularies

Shelby Livingston

Senior health tech reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Doug Williams returns with a ‘FIT’ bet on CAR-Ts; Biogen appoints Mene Pangalos to board

Corrected: Roche’s Tecentriq scores first US approval for subcutaneous PD-L1

Neurocrine culls Phase 2 neuropsych med after failing to validate earlier data

Bicara, Zenas and MBX rekindle IPO market with rare Friday tripleheader

Aurinia restructures board, bringing in Kevin Tang and keeping CEO

An­oth­er ma­jor PBM will cut Ab­b­Vie's Hu­mi­ra from its largest com­mer­cial for­mu­la­ries

Senior health tech reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Another major PBM will cut AbbVie's Humira from its largest commercial formularies